Privium Fund Management B.V. Has $5.27 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Privium Fund Management B.V. trimmed its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 22.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 62,232 shares of the company's stock after selling 18,000 shares during the quarter. Axsome Therapeutics comprises 1.2% of Privium Fund Management B.V.'s holdings, making the stock its 18th largest position. Privium Fund Management B.V. owned approximately 0.13% of Axsome Therapeutics worth $5,265,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $52,000. R Squared Ltd acquired a new position in Axsome Therapeutics in the 4th quarter valued at about $64,000. KBC Group NV grew its position in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after acquiring an additional 385 shares during the period. Moors & Cabot Inc. acquired a new stake in shares of Axsome Therapeutics during the 3rd quarter worth about $200,000. Finally, Xponance Inc. increased its position in shares of Axsome Therapeutics by 11.6% during the fourth quarter. Xponance Inc. now owns 2,659 shares of the company's stock valued at $225,000 after acquiring an additional 277 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Royal Bank of Canada boosted their price objective on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 19th. HC Wainwright restated a "buy" rating and issued a $200.00 price target on shares of Axsome Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company boosted their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Truist Financial raised their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Mizuho boosted their target price on Axsome Therapeutics from $195.00 to $212.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $167.36.

Remove Ads

Insider Buying and Selling

In other news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Performance

NASDAQ AXSM traded up $0.52 during trading hours on Friday, hitting $126.79. The company had a trading volume of 789,781 shares, compared to its average volume of 640,623. The firm has a market cap of $6.18 billion, a P/E ratio of -21.17 and a beta of 0.99. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The business has a fifty day simple moving average of $116.56 and a 200-day simple moving average of $100.17.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Equities analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.